Generating a Synthetic Dataset for Kidney Transplantation Using Generative Adversarial Networks and Categorical Logit Encoding

Total Page:16

File Type:pdf, Size:1020Kb

Generating a Synthetic Dataset for Kidney Transplantation Using Generative Adversarial Networks and Categorical Logit Encoding GENERATING A SYNTHETIC DATASET FOR KIDNEY TRANSPLANTATION USING GENERATIVE ADVERSARIAL NETWORKS AND CATEGORICAL LOGIT ENCODING John Bartocci A Thesis Submitted to the Graduate College of Bowling Green State University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE May 2021 Committee: Robert C. Green II, Advisor Sankardas Roy Qing Tian Copyright ©May 2021 John Bartocci All rights reserved iii ABSTRACT Robert C. Green II, Advisor A synthetic data set for kidney transplantation is developed using a Wasserstein generative ad- versarial network (WGAN) and a donor-recipient HLA matching algorithm. Like many medical data sets, much of the kidney transplant data set is categorical. A new method for dealing with cat- egorical data in GANs is proposed and the results are analyzed. The real-valued data is prepared with a process similar to one-hot encoding, but instead of using ones and zeros, the values are logit in nature, with a large positive value corresponding to one and large negative value corresponding to zero. By capturing the logit distributions and correlations between categories within a GAN, the generator can create a synthetic version of the data that will resemble the real, un-encoded data set after a softmax function is applied and values are stochastically selected. While the statistical met- ric used demonstrated that the synthetic and real data sets did not come from the same distribution, a visual inspection shows general similarity between the two data sets. A rematching simulation performed on the real and synthetic data set shows relatively similar results. iv To my wife, for all the love and encouragement during these interesting times. v ACKNOWLEDGMENTS I would like to thank Dr. Green for his support and guidance during my graduate career. His dedication to his students was an inspiration. I would also like to acknowledge the help that Dr. Bekbolsynov provided during the early phases of my thesis when working with drug regimens. I would also like to thank Dr. Tian and Dr. Roy for their valuable feedback on my thesis. The data reported here have been supplied by the Hennepin Healthcare Research Institute (HHRI) as the contractor for the Scientific Registry of Transplant Recipients (SRTR). The in- terpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy of or interpretation by the SRTR or the U.S. Government. Principles of the Helsinki declaration were followed when working with SRTR data. vi TABLE OF CONTENTS Page CHAPTER 1 INTRODUCTION . 1 CHAPTER 2 RELATED WORKS AND BACKGROUND INFORMATION . 4 2.1 Generative Adversarial Neural Networks . 4 2.2 Synthetic Electronic Health Records . 7 2.3 Privacy Evaluation . 7 2.4 Synthetic Data Quality Evaluation . 7 2.5 Generation of Kidney Transplant Data . 8 CHAPTER 3 METHODOLOGY . 9 3.1 Data Set Preparation . 9 3.1.1 Data Cleaning . 10 3.1.2 Induction Drug Columns . 10 3.1.3 Maintenance Drug Columns . 13 3.1.4 Data Set Summary . 14 3.2 Method Overview . 16 3.3 Categorical Encoding . 17 3.4 WGAN with Logit-based Critic (WGAN-LC) . 18 3.5 Random Sampling of Conditional Probability Distributions . 20 3.6 Donor and Recipient Matching Algorithm . 22 CHAPTER 4 RESULTS . 24 4.1 Platform . 24 4.2 Patient Medical Profile Results . 25 4.3 Age Assignment Results . 31 4.4 Donor and Recipient Matching Results . 34 4.5 Rematching Results . 40 vii CHAPTER 5 CONCLUSION . 42 5.1 Future Work . 42 BIBLIOGRAPHY . 44 APPENDIX A SELECT PYTHON CODE FRAGMENTS . 48 viii LIST OF FIGURES Figure Page 2.1 Generic GAN setup. 5 3.1 Example of the process used to develop the induction drug columns. 12 3.2 Example of the process used to develop the maintenance drug columns. 16 3.3 Example of the process used to encode the categorical data. 18 3.4 WGAN architecture using logit-encoded categorical data. 19 4.1 Patient profile frequency distributions, part 1 of 5. 26 4.2 Patient profile frequency distributions, part 2 of 5. 27 4.3 Patient profile frequency distributions, part 3 of 5. 28 4.4 Patient profile frequency distributions, part 4 of 5. 29 4.5 Patient profile frequency distributions, part 5 of 5. 30 4.6 Comparison between the real donor and recipient data CW1 HLA distributions. 31 4.7 Age distribution plots for real and synthetic data sets. 32 4.8 Age distribution plots for real and synthetic data sets for white males. 33 4.9 Distribution plots for donor columns in matched data sets, part 1 of 2. 36 4.10 Distribution plots for donor columns in matched data sets, part 2 of 2. 37 4.11 Distribution plots for recipient columns in matched data sets, part 1 of 2. 38 4.12 Distribution plots for recipient columns in matched data sets, part 2 of 2. 39 4.13 Rematching results on real and synthetic data sets. 41 ix LIST OF TABLES Table Page 3.1 Donor column descriptions and data types [4]. 10 3.2 Candidate column descriptions and data types [4]. 11 3.3 Transplant column descriptions and data types [4]. 11 3.4 The disposition of missing data that was not dropped. 12 3.5 Induction drug categories. 13 3.6 Drugs categorized as ”other”. 13 3.7 Description of categories used to summarize the induction data. 14 3.8 Maintenance drug categories. 15 3.9 Maintenance regimens. 15 3.10 Description of categories used to summarize the maintenance regimens. 16 3.11 Patient information columns and their data types that are generated by the WGAN. 21 3.12 Summary of the dimensions and activation functions in the generator architecture. 21 3.13 Summary of the dimensions and activation functions in the critic architecture. 21 3.14 Key values used in the generator and critic models. 22 4.1 Fisher-Exact results for the patient profile data generated by the WGAN. 25 4.2 Fisher-Exact results for the paired patient data. 35 1 CHAPTER 1 INTRODUCTION Machine learning has seen major advances in a wide variety of domains in recent years. While the medical domain has seen its share of advances, one major challenge that has impeded its progress is the lack of publicly available data sets. Medical data, by its very nature, routinely contains protected health information (PHI) and in the US is regulated by HIPAA privacy rules. According to [1], one possibility to solve this issue is through de-identification of the PHI. When de-identification is not feasible due to restrictions or disclosure risk, another option is generating a synthetic data set. Specifically, this research focused on assembling a synthetic dataset for kidney transplantation. While generating a synthetic data set solves many of the privacy concerns, it is not a panacea for privacy [2]. Synthetic data also has its own challenges, such as evaluating the quality of the data set, handling categorical and time-series data, and architecture specific challenges such as mode col- lapse with generative adversarial networks (GANs) [3]. While knowledge of the domain-specific nature of any given medical data set would be helpful, it is not a requirement to understanding the more general issues and methods presented in this thesis for handling and generating categorical data. The SRTR Kidney transplant dataset [4] has a significant number of categorical columns with many different levels. In order to generate a synthetic version of such a dataset, the more general issue of synthesizing categorical data with GANs must be addressed. This research attempted to simplify the deployment of GANs for categorical data, by training in the latent space that contains the continuous distribution of logits by encoding the real data in a logit-like manner. This elimi- nated the need for stochastic selection from softmax during training or for a distribution that can be hardened via a temperature parameter, like the Gumbel-Softmax [5]. This thesis attempted to reduce the number of joint distributions to emphasize the other joint distributions that are captured by breaking the data generation up into functional units. This syn- thetic data generation treated the generation of the donor and recipient data separately and then 2 worked to combine them using a matching simulation. This functional data aggregation should in- crease the level of privacy in the synthetic data set while attempting to maintain the most important join distributions. While a statistical analysis is performed on the resultant data using a Fisher-Exact test, the limitations of statistical analysis on nominal categorical data necessitate some visual inspection of the distributions. The results of the Fisher-Exact test demonstrate that the synthetic data set generated by this method and another data set generated by the Synthetic Data Vault (SDV) [6] both fail to pull from the same distribution as the real data set. The distribution plots, however, show that some of the distribution information has been captured with this method. Additionally, the machine learning efficacy test provides some hints that the synthetic data set can generate some machine learning insights for rematching algorithms. Considering these issues, this thesis makes three contributions regarding data related to kidney transplantation including: 1. A proposal for a new method to train a WGAN using raw logits for categorical data as direct input to a critic; 2. A phased process to build up a synthetic data set using different methods; and 3. The application of the previous two contributions to partially generate a synthetic data set for kidney transplants that is similar to the actual data set. Stated differently, this thesis centers on answering three questions: 1. Can a Wasserstein GAN (WGAN) generate categorical data while avoiding the need for Gumbel-Softmax by using a logit output layer on the generator and encoding the real data in a logit-like scheme? 2.
Recommended publications
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti Et Al
    US 20170209462A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti et al. (43) Pub. Date: Jul. 27, 2017 (54) BTK INHIBITOR COMBINATIONS FOR Publication Classification TREATING MULTIPLE MYELOMA (51) Int. Cl. (71) Applicant: Pharmacyclics LLC, Sunnyvale, CA A 6LX 3/573 (2006.01) A69/20 (2006.01) (US) A6IR 9/00 (2006.01) (72) Inventors: Elizabeth Bilotti, Sunnyvale, CA (US); A69/48 (2006.01) Thorsten Graef, Los Altos Hills, CA A 6LX 3/59 (2006.01) (US) A63L/454 (2006.01) (52) U.S. Cl. CPC .......... A61 K3I/573 (2013.01); A61K 3 1/519 (21) Appl. No.: 15/252,385 (2013.01); A61 K3I/454 (2013.01); A61 K 9/0053 (2013.01); A61K 9/48 (2013.01); A61 K (22) Filed: Aug. 31, 2016 9/20 (2013.01) (57) ABSTRACT Disclosed herein are pharmaceutical combinations, dosing Related U.S. Application Data regimen, and methods of administering a combination of a (60) Provisional application No. 62/212.518, filed on Aug. BTK inhibitor (e.g., ibrutinib), an immunomodulatory agent, 31, 2015. and a steroid for the treatment of a hematologic malignancy. US 2017/0209462 A1 Jul. 27, 2017 BTK INHIBITOR COMBINATIONS FOR Subject in need thereof comprising administering pomalido TREATING MULTIPLE MYELOMA mide, ibrutinib, and dexamethasone, wherein pomalido mide, ibrutinib, and dexamethasone are administered con CROSS-REFERENCE TO RELATED currently, simulataneously, and/or co-administered. APPLICATION 0008. In some aspects, provided herein is a method of treating a hematologic malignancy in a subject in need 0001. This application claims the benefit of U.S.
    [Show full text]
  • Pharmaceuticals and Medical Devices Safety Information No
    Pharmaceuticals and Medical Devices Safety Information No. 263 November 2009 Table of Contents 1. Association between use of human insulin and insulin analogues and risk of cancer ....................................................................................... 4 2. Important Safety Information .................................................................. 7 .1. Ivermectin ································································································ 7 .2. Everolimus, gusperimus hydrochloride, cyclosporine (oral dosage form, injectable dosage form), tacrolimus hydrate (oral dosage form, injectable dosage form), basiliximab (genetical recombination), mycophenolate mofetil, muromonab-CD3 ···· 9 .3. Ciprofloxacin, ciprofloxacin hydrochloride ······················································ 15 .4. Sunitinib malate ······················································································ 18 .5. Sorafenib tosilate ····················································································· 21 .6. Tegafur/gimeracil/oteracil potassium ···························································· 23 .7. Bevacizumab (genetical recombination) ······················································· 25 .8. Rosuvastatin calcium ················································································ 29 3. Revision of PRECAUTIONS (No. 210) (1) Pancuronium bromide, vecuronium bromide, rocuronium bromide (and 7 others) ··· 31 (2) Blood circuits (and 3 others) ·······································································
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Prescription Medications, Drugs, Herbs & Chemicals Associated With
    Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, or by any means, without the prior written permission of the American Tinnitus Association. ©2013 American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association This document is to be utilized as a conversation tool with your health care provider and is by no means a “complete” listing. Anyone reading this list of ototoxic drugs is strongly advised NOT to discontinue taking any prescribed medication without first contacting the prescribing physician. Just because a drug is listed does not mean that you will automatically get tinnitus, or exacerbate exisiting tinnitus, if you take it. A few will, but many will not. Whether or not you eperience tinnitus after taking one of the listed drugs or herbals, or after being exposed to one of the listed chemicals, depends on many factors ‐ such as your own body chemistry, your sensitivity to drugs, the dose you take, or the length of time you take the drug. It is important to note that there may be drugs NOT listed here that could still cause tinnitus. Although this list is one of the most complete listings of drugs associated with tinnitus, no list of this kind can ever be totally complete – therefore use it as a guide and resource, but do not take it as the final word. The drug brand name is italicized and is followed by the generic drug name in bold.
    [Show full text]
  • Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of Ro5459072 in Patients with Primary Sjögren’S Syndrome
    Official Title: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP PHASE 2A STUDY TO ASSESS THE EFFICACY OF RO5459072 IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME NCT Number: NCT02701985 Document Dates: Protocol Version 3: 30-Oct-2016 PROTOCOL TITLE: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2A STUDY TO ASSESS THE EFFICACY OF RO5459072 IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME PROTOCOL NUMBER: BP30037 VERSION: 3 EUDRACT NUMBER: 2015-004476-30 IND NUMBER: 128528 TEST PRODUCT: RO5459072 SPONSOR: F. Hoffmann-La Roche Ltd DATE FINAL: Version 1: 28 January 2016 DATE AMENDED Version 2: 01 August 2016 Version 3: See electronic date stamp below FINAL PROTOCOL APPROVAL Approver's Name Title Date and Time (UTC) Translational Medicine Leader 30-Oct-2016 15:40:47 CONFIDENTIAL STATEMENT The information contained in this document, especially any unpublished data, is the property of F.Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board. It is understood that this information will not be disclosed to others without written authorization from Roche except to the extent necessary to obtain informed consent from persons to whom the drug may be administered. RO5459072— F. Hoffmann-La Roche Ltd Protocol BP30037 Version 3 PROTOCOL AMENDMENT, VERSION 3: RATIONALE Protocol BP30037 has been amended to incorporate the following changes to the protocol: Section 4.2.3: Implementation of changes to eligibility criteria . The eligibility criteria of the protocol have therefore been amended to mandate testing for tuberculosis and exclude patients with positive results.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,916,910 Lai (45) Date of Patent: Jun
    USOO591.6910A United States Patent (19) 11 Patent Number: 5,916,910 Lai (45) Date of Patent: Jun. 29, 1999 54 CONJUGATES OF DITHIOCARBAMATES Middleton et al., “Increased nitric oxide synthesis in ulcer WITH PHARMACOLOGICALLY ACTIVE ative colitis” Lancet, 341:465-466 (1993). AGENTS AND USES THEREFORE Miller et al., “Nitric Oxide Release in Response to Gut Injury Scand. J. Gastroenterol., 264:11-16 (1993). 75 Inventor: Ching-San Lai, Encinitas, Calif. Mitchell et al., “Selectivity of nonsteroidal antiinflamatory drugs as inhibitors of constitutive and inducible cyclooxy 73 Assignee: Medinox, Inc., San Diego, Calif. genase” Proc. Natl. Acad. Sci. USA, 90:11693–11697 (1993). 21 Appl. No.: 08/869,158 Myers et al., “Adrimaycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor Response' Science, 22 Filed: Jun. 4, 1997 197:165-167 (1977). 51) Int. Cl. ...................... C07D 207/04; CO7D 207/30; Onoe et al., “Il-13 and Il-4 Inhibit Bone Resorption by A61K 31/27; A61K 31/40 Suppressing Cyclooxygenase-2-Dependent ProStaglandin 52 U.S. Cl. .......................... 514/423: 514/514; 548/564; Synthesis in Osteoblasts' J. Immunol., 156:758–764 548/573; 558/235 (1996). 58 Field of Search ..................................... 514/514, 423; Reisinger et al., “Inhibition of HIV progression by dithio 548/565,573; 558/235 carb” Lancet, 335:679–682 (1990). Schreck et al., “Dithiocarbamates as Potent Inhibitors of 56) References Cited Nuclear Factor KB Activation in Intact Cells' J. Exp. Med., 175:1181–1194 (1992). U.S. PATENT DOCUMENTS Slater et al., “Expression of cyclooxygenase types 1 and 2 in 4,160,452 7/1979 Theeuwes ..............................
    [Show full text]
  • 58 69 Success of the European Orphan Medicines Regime.Fm
    Cross-border Life Sciences 2003 The success of the European orphan medicines regime Peter Bogaert, Covington & Burling www.practicallaw.com/A27971 In April, 2000, a totally new European orphan medicines regime 2309/93 - entitles an applicant to obtain a marketing authorisa- came into effect. This was many years after adoption of a similar tion if the application complies with the requirements set out in incentive scheme in the US and examples in other countries, that legislation (see, for instance, the decision of 7th December, such as Japan. The rules are intended to provide incentives for 1993 of the ECJ in Pierrel SpA and others v Ministero della research and development of medicines intended for the Sanità, Case C-83/92). treatment, prevention or diagnosis of rare disorders that otherwise would not be pursued by industry in light of the limited Preparatory policy work carried out between 1993 and 1996 chances of return on investment. It is estimated that there are ultimately resulted in a formal Commission proposal for a between 5,000 and 8,000 such rare disorders in the world, the European orphan medicines regime in August 1996. Following a majority of which are of a genetic origin, and that up to 30 million highly efficient and constructive legislative procedure, on 16th people affected by one of these rare diseases live in the EU. December, 1999 the European Parliament and the Council adopted the basic text (Regulation No. 141/2000 of the The regime is intensively used by industry and overall is quite European Parliament and the Council of 16th December, 1999 successful, although it has not yet reached full maturity.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Targeting the Monocyte–Macrophage Lineage in Solid Organ Transplantation
    REVIEW published: 16 February 2017 doi: 10.3389/fimmu.2017.00153 Targeting the Monocyte–Macrophage Lineage in Solid Organ Transplantation Thierry P. P. van den Bosch†, Nynke M. Kannegieter†, Dennis A. Hesselink, Carla C. Baan and Ajda T. Rowshani* Department of Internal Medicine, Section of Nephrology and Transplantation, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands There is an unmet clinical need for immunotherapeutic strategies that specifically target the active immune cells participating in the process of rejection after solid organ transplantation. The monocyte–macrophage cell lineage is increasingly recognized as a major player in acute and chronic allograft immunopathology. The dominant presence of cells of this lineage in rejecting allograft tissue is associated with worse graft function and survival. Monocytes and macrophages contribute to alloimmunity via diverse pathways: antigen processing and presentation, costimulation, pro-inflammatory cytokine production, and tissue repair. Cross talk with other recipient immune competent cells and Edited by: donor endothelial cells leads to amplification of inflammation and a cytolytic response Zhenhua Dai, Guangdong Provincial Academy of in the graft. Surprisingly, little is known about therapeutic manipulation of the function Chinese Medical Sciences, China of cells of the monocyte–macrophage lineage in transplantation by immunosuppressive Reviewed by: agents. Although not primarily designed to target monocyte–macrophage lineage Beatrice Charreau, cells, multiple categories of currently prescribed immunosuppressive drugs, such as University of Nantes, France Philippe Saas, mycophenolate mofetil, mammalian target of rapamycin inhibitors, and calcineurin Etablissement Français du Sang, inhibitors, do have limited inhibitory effects. These effects include diminishing the degree France of cytokine production, thereby blocking costimulation and inhibiting the migration of *Correspondence: Ajda T.
    [Show full text]
  • Gusperimus Hydrochloride (Rinnm) 1
    1834 Immunosuppressants inducers or competitive inhibitors of P-glycoprotein, or hepatic Uses and Administration 2. Grube E, Buellesfeld L. Everolimus for stent-based intracoro- enzymes, particularly cytochrome P450 isoenzyme CYP3A4. Everolimus is a derivative of sirolimus (p.1841). It is used as a nary applications. Rev Cardiovasc Med 2004; 5 (suppl): S3–S8. Use with live vaccines should be avoided. proliferation signal inhibitor in the prevention of graft rejection 3. Tsuchiya Y, et al. Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am J Car- episodes in patients undergoing renal or cardiac transplantation diol 2006; 98: 464–9. ◊ References. as part of an immunosuppressive regimen that includes 1. Kovarik JM, et al. Everolimus drug interactions: application of a 4. Ormiston JA, et al. First-in-human implantation of a fully bioab- ciclosporin (microemulsifying) and corticosteroids. The recom- sorbable drug-eluting stent: the BVS poly-L-lactic acid classification system for clinical decision making. Biopharm mended adult oral dose is 750 micrograms twice daily, begun as Drug Dispos 2006; 27: 421–6. everolimus-eluting coronary stent. Catheter Cardiovasc Interv soon as possible after transplantation, and given at the same time 2007; 69: 128–31. Immunosuppressants. The bioavailability of everolimus was as ciclosporin (see Administration, below). Doses of everolimus 5. Beijk MA, Piek JJ. XIENCE V everolimus-eluting coronary significantly increased when given with ciclosporin,1 and dose should be reduced in patients with hepatic impairment, see be- stent system: a novel second generation drug-eluting stent. Ex- adjustment of everolimus may be necessary if the ciclosporin low.
    [Show full text]